Common Technical Document (CTD): Definition, Modules, and ICH M4 Guidelines

The Common Technical Document (CTD) is a globally harmonized dossier format used for regulatory submissions of medicinal products. The CTD standardizes how quality, nonclinical, and clinical data are structured and presented for regulatory review. The CTD format was developed by the International Council for Harmonisation (ICH) in collaboration with major regulatory authorities, including the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and Japan’s Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA).

The primary purpose of the CTD is to enable consistent, efficient assessments across regions while reducing duplication by allowing a single core scientific dossier to support submissions in multiple countries.

The CTD is structured into five modules as outlined below.

1. Module 1 – Administrative Information and Prescribing Information: Region-specific forms, legal documents, and labeling/product information.
2. Module 2 – CTD Summaries: Expert overviews and summaries that interpret Modules 3–5 and guide reviewers.
3. Module 3 – Quality (CMC): Chemistry, manufacturing, and controls information for the drug substance and drug product.
4. Module 4 – Nonclinical Study Reports: Pharmacology, pharmacokinetics, and toxicology data from laboratory and animal studies.
5. Module 5 – Clinical Study Reports: Human clinical evidence supporting safety and efficacy, including relevant post-marketing experience when available.

Preparation and organization of CTD content are governed by the ICH M4 Guidelines. M4 defines overall dossier structure, M4Q addresses quality (Module 3), M4S standardizes nonclinical safety (Module 4), and M4E structures clinical evidence (Module 5). While the CTD defines dossier content and organization, the eCTD is the electronic format used to submit and maintain the same CTD content throughout its lifecycle.

The CTD is a living dossier that evolves over the medicinal product lifecycle, from development and registration to post-approval changes, pharmacovigilance activities, and lifecycle optimization. Marketing Authorization Holders (MAHs) are responsible for maintaining CTD accuracy through controlled updates, documentation governance, and ongoing regulatory submissions.

SimplerQMS supports CTD preparation and maintenance by strengthening document control, change management, training oversight, and audit-ready traceability. SimplerQMS helps reduce documentation errors, support regulatory compliance, and improve submission timelines across the product lifecycle by centralizing records and standardizing workflows.

What Is the Common Technical Document (CTD)?

The Common Technical Document (CTD) is a globally harmonized format used to prepare regulatory submissions for medicinal products. The CTD organizes quality, safety, and clinical data into a standardized structure, allowing regulatory authorities to review applications consistently across regions.

The purpose of the CTD in regulatory submissions is to simplify and unify marketing authorization applications. A common structure enables regulators to assess dossiers more efficiently, while pharmaceutical companies use a single core dossier to support submissions in multiple countries.

The CTD was established to facilitate regulatory harmonization and enhance collaboration among key regulatory authorities. Development of the CTD aimed to shorten review timelines, improve predictability for applicants, and align scientific evaluation standards across regions.

The CTD reduces duplication and streamlines global regulatory submissions by enabling companies to prepare a single, harmonized dossier with consistent core content. Before the CTD, each regulatory authority required a different dossier format, forcing companies to recompile the same data repeatedly. With the CTD, regional administrative requirements remain separate, while scientific data are reused without restructuring, reducing administrative burden and rework.

The organizations that developed the CTD include the International Council for Harmonisation (ICH) in collaboration with the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and Japan’s Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA). Their joint effort established a shared regulatory framework for medicinal product submissions.

The regulatory authorities that use or require the CTD include the FDA, EMA, MHLW/PMDA, Health Canada, Swissmedic, and many other ICH and non-ICH agencies worldwide. Adoption of the CTD continues to expand among regulatory agencies because the format improves transparency, consistency, and regulatory decision-making.

At a high level, the CTD includes five modules covering regional administrative information, summaries and overviews, quality documentation, nonclinical study reports, and clinical study reports. These modules provide the complete scientific and administrative evidence required to support a marketing authorization application.

Which Companies Use the CTD?

Pharmaceutical and biotechnology companies, including innovator companies, generic manufacturers, biosimilar developers, and combination-product sponsors, use the CTD to organize quality, safety, and efficacy data for global regulatory submissions. Pharmaceutical and biotechnology companies rely on the CTD because it provides a harmonized structure for presenting regulatory data across multiple regions.

Using the CTD allows companies to prepare a single core dossier that can be reused globally, reducing duplication, regulatory effort, and submission timelines. Smaller organizations often collaborate with Contract Research Organizations (CROs) to compile, structure, and validate CTD content for regulatory review.

How Does CTD Differ from eCTD?

The Common Technical Document (CTD) differs from the electronic Common Technical Document (eCTD) in the submission format rather than in the scientific content.

The CTD defines the standardized structure and content of a regulatory dossier by organizing information into five modules. The electronic Common Technical Document (eCTD) is an electronic submission format that applies XML backbone files, hyperlinks, metadata, and lifecycle management to the same CTD content. In practice, the CTD defines the dossier framework, while the eCTD provides the digital technology that enables efficient, traceable, and regulator-ready submissions.

What Are the 5 CTD Modules?

The five modules of the CTD form the standardized CTD Structure, visualized as the CTD Triangle, reflecting how the content progresses from regional administrative information to detailed scientific evidence.

The five CTD modules are listed below.

1. Module 1 – Administrative Information and Prescribing Information: Module 1 contains region-specific administrative, regulatory, and legal documentation. Module 1 includes the application form, applicant details, proposed labeling and product information, qualified expert declarations, risk management systems, and jurisdiction-specific requirements such as exclusivity provisions and environmental assessments. Regulatory authorities use Module 1 to verify the eligibility, administrative compliance, and procedural requirements of applicants before scientific review begins.
2. Module 2 – CTD Summaries: Module 2 provides high-level summaries and expert overviews of quality, nonclinical, and clinical data. Module 2 includes the pharmacological profile, key safety and efficacy summaries, and risk–benefit assessment. Reviewers rely on Module 2 to understand the overall scientific rationale of the submission before examining the detailed supporting modules.
3. Module 3 – Quality: Module 3 contains the full chemistry, manufacturing, and controls (CMC) information. Module 3 covers drug substance composition and properties, drug product formulation, manufacturing processes, quality controls, specifications, stability data, and packaging systems. Module 3 demonstrates that the medicinal product is manufactured consistently and meets defined quality standards.
4. Module 4 – Nonclinical Study Reports: Module 4 includes results from nonclinical studies conducted in laboratory and animal models. Module 4 contains toxicology data, pharmacokinetic and pharmacodynamics studies, safety pharmacology assessments, and supporting efficacy data. Regulators use Module 4 to evaluate the nonclinical safety profile and determine whether the product is suitable for clinical use in humans.
5. Module 5 – Clinical Study Reports: Module 5 provides detailed reports from human clinical trials. Module 5 includes clinical study protocols, study designs, statistical methodologies, participant demographics, and inclusion and exclusion criteria. It contains biopharmaceutical studies, clinical pharmacology studies, safety and efficacy results from Phase I through Phase III trials, as well as post-marketing data when available. Module 5 provides the primary evidence supporting the product’s safety, efficacy, and approval for use in humans.

CTD Module 1: Administrative Information (Regional)

CTD Module 1 is the region-specific administrative and legal component of the CTD. Module 1 contains all non-scientific information required by a regulatory authority to validate, accept, and manage a marketing authorization application. This administrative module is defined by local regulatory frameworks and therefore varies by region.

The sections included in CTD Module 1 for EU regulatory submissions are outlined below.

• Cover Letter (Section 1.0): The cover letter introduces the submission, identifies the application type, and regulatory procedure. The cover letter explains the submission scope, context, and any supporting documentation submitted alongside the dossier.
• Application Form (Section 1.2): The application form provides official submission details, including applicant information, product identifiers, procedure type (centralised, decentralised, or mutual recognition), and administrative declarations required by EU authorities.
• Product Information (Section 1.3): Product information defines the proposed summary of product characteristics, labeling, and package leaflet content, formatted and translated to meet regional regulatory and language requirements.
• Mock-ups and Specimens (Sections 1.3.2 and 1.3.3): Mock-ups and specimens demonstrate how the product labeling and packaging will appear on the market, allowing regulators to verify compliance with regional presentation and patient information standards.
• Consultation with Target Patient Groups (Section 1.3.4): Consultation with target patient groups documents patient group consultations related to package leaflet readability and usability, where required by regional legislation.
• Previously Approved Product Information (Section 1.3.5): Previously approved product information provides currently approved labeling and product information from relevant Member States to support regulatory alignment and mutual recognition procedures.
• Braille Information (Section 1.3.6): Braille documentation demonstrates compliance with regional requirements for accessible labeling and packaging for visually impaired patients.
• Information About the Experts (Section 1.4): Information about the experts identifies the qualified experts responsible for the quality, nonclinical, and clinical sections and confirms their accountability for the scientific content.
• Specific Application Requirements (Section 1.5): Specific application documentation addresses legal-basis-dependent requirements, such as generic, biosimilar, bibliographic, conditional, or exceptional circumstance applications.
• Environmental Risk Assessment (Section 1.6): The environmental risk assessment evaluates the potential environmental impact of the medicinal product, including GMO or non-GMO considerations where applicable.
• Orphan Drug Information (Section 1.7): Orphan drug information documents orphan designation status, similarity assessments, and market exclusivity conditions when applicable.
• Pharmacovigilance Information (Section 1.8): Pharmacovigilance information describes the pharmacovigilance and risk management systems in place to monitor, evaluate, and manage the safety of the medicinal product throughout its lifecycle.
• Clinical Trial Information (Section 1.9): Clinical trial information provides details of ongoing or completed clinical trials to support regulatory oversight and compliance with regional trial requirements.
• Paediatric Information (Section 1.10): Paediatric information includes Paediatric Investigation Plans (PIPs) and related documentation required under regional paediatric legislation.
• Responses to Regulatory Questions: Responses to regulatory questions document formal replies, commitments, and supporting data submitted during the review process.
• Additional Regional Documentation: Additional regional documentation includes authority-specific certificates, declarations, procedural documents, or administrative materials required under local regulations.

CTD Module 1 varies by region because each regulatory authority defines its own administrative, legal, and procedural submission requirements. Regional differences include application templates, document formats, language requirements, numbering conventions, document placement rules, and procedural workflows.

The primary purpose of CTD Module 1 is to establish the legal, procedural, and administrative validity of a submission before scientific assessment begins. CTD Module 1 ensures that all regional requirements are met and provides regulators with the information needed to process and manage the application. CTD Module 1 is important in regulatory review because it determines whether a submission can be validated and proceeds to scientific evaluation. Regulators rely on this module to confirm procedural compliance, legal standing, and completeness.

Errors or missing administrative or labeling documents can delay validation or prevent review initiation. A complete and accurate Module 1 enables timely acceptance and allows regulators to focus on the scientific assessment of Modules 2–5.

CTD Module 2: CTD Summaries (The QOS)

CTD Module 2 is the scientific summary and interpretation component of the common technical document. CTD Module 2 provides high-level scientific expert summaries that explain and contextualize the detailed data presented in Modules 3, 4, and 5. Module 2 acts as the analytical bridge between administrative content and full technical documentation.

The sections included in CTD Module 2 are listed below.

• CTD Table of Contents (Section 2.1): The CTD table of contents provides a structured overview of the entire dossier. Section 2.1 enables reviewers to navigate efficiently across modules and locate supporting documentation quickly during the assessment process.
• CTD Introduction (Section 2.2): The CTD introduction briefly describes the medicinal product, its pharmacological class, mechanism of action, and proposed clinical use. Section 2.2 sets the scientific context for the submission and remains concise by design.
• Quality Overall Summary (QOS) (Section 2.3): The quality overall summary summarizes key aspects of drug substance and drug product quality. The QOS highlights manufacturing processes, control strategies, specifications, analytical methods, stability, and compliance with quality standards, while clearly referencing detailed evidence in Module 3.
• Nonclinical Overview (Section 2.4): The nonclinical overview evaluates pharmacology, pharmacokinetics, and toxicology data. Section 2.4 interprets findings from animal and laboratory studies, and explains how nonclinical results support safe clinical development and proposed therapeutic use, referencing detailed studies provided in Module 4.
• Clinical Overview (Section 2.5): The clinical overview provides an integrated critical analysis of the clinical development program. Section 2.5 focuses on clinical pharmacology, safety, efficacy, dose justification, and benefit–risk assessment, supported by detailed clinical data presented in Module 5.
• Nonclinical Written and Tabulated Summaries (Section 2.6): The summaries present structured descriptions and tables that consolidate nonclinical study results. This format allows regulators to review trends, key findings, and study outcomes without examining each individual report.
• Clinical Summary (Section 2.7): The clinical summary presents consolidated clinical study data across development phases. Section 2.7 summarizes study designs, populations, efficacy results, and safety outcomes in a structured and comparable format.

CTD Module 2 follows a harmonized structure defined by ICH guidelines and is prepared consistently across regions. Regulators expect close alignment between Module 2 summaries and the detailed evidence in Modules 3, 4, and 5 because the content of Module 2 is scientific rather than administrative.

The purpose of CTD Module 2 is to organize, summarize, and interpret complex scientific evidence. Module 2 presents an integrated interpretation of quality, nonclinical, and clinical data that supports the proposed use of the medicinal product and guides the regulatory review process.

Reviewers rely on Module 2 to form an initial scientific understanding of the dossier and to navigate the detailed documentation that follows. Well-prepared summaries improve review efficiency, reduce requests for clarification, and support consistent regulatory decision-making. Weak or inconsistent narratives can delay evaluation even when supporting data are complete.

CTD Module 3: Quality (CMC)

CTD Module 3 is the quality-focused component of the Common Technical Document and provides detailed Chemistry, Manufacturing, and Controls (CMC) information for the medicinal product. CTD Module 3 explains how the drug substance and drug product are developed, manufactured, controlled, and maintained to ensure consistent quality throughout the product lifecycle. Module 3 follows the harmonized CTD structure defined by ICH and forms the quality backbone of the regulatory dossier.

Below are listed the sections included in CTD Module 3.

• 3.2.S – Drug Substance: Section 3.2.S describes the active pharmaceutical ingredient (API). The drug substance section covers general information, manufacturing processes, characterization, control of materials, specifications, analytical methods, reference standards, container closure systems, and stability data. Section 3.2.S demonstrates the identity, purity, strength, and consistency of the drug substance.
• 3.2.P – Drug Product: Section 3.2.P focuses on the finished medicinal product. The drug product section includes pharmaceutical development, formulation, manufacturing processes, in-process controls, control of excipients, specifications, analytical procedures, reference standards, validation data, container closure systems, and stability studies. Section 3.2.P explains how the final product is manufactured and maintained within approved quality specifications.
• 3.2.A – Appendices: Section 3.2.A contains supporting information related to facilities, equipment, adventitious agent safety, and novel excipients when applicable. Section 3.2.A provide additional context that supports the main CMC sections.
• 3.2.R – Regional Information: Section 3.2.R includes region-specific quality information required by certain regulatory authorities. This section complements the harmonized CMC content with local regulatory requirements without altering the core structure of Module 3.

CTD Module 3 provides assurance that the medicinal product supplied to patients is manufactured consistently and controlled in accordance with defined quality standards. The module demonstrates that quality is built into every stage of manufacturing and control.

Regulatory authorities rely on CTD Module 3 to evaluate manufacturing reliability, process robustness, control strategies, and product consistency. Incomplete or inconsistent information in Sections 3.2.S or 3.2.P can trigger clarification requests or delay approval. A well-prepared Module 3 supports efficient review, inspection readiness, and long-term regulatory compliance.

CTD Module 4: Nonclinical Study Reports (Safety)

CTD Module 4 is the nonclinical component of the Common Technical Document and contains detailed study reports generated from laboratory and animal investigations. CTD Module 4 evaluates the nonclinical profile of the medicinal product, including pharmacology, pharmacokinetics, and toxicology, to assess biological activity, exposure, and potential safety risks, and to support decisions on the initiation and continuation of clinical development in humans.

CTD Module 4 follows the harmonized ICH CTD structure and provides the scientific foundation for assessing risk prior to and alongside clinical development.

The sections included in CTD Module 4 are outlined below.

• Table of Contents (Section 4.1): Section 4.1 provides a structured index of all nonclinical study reports included in Module 4. The table of contents enables regulators to quickly locate specific studies and review the nonclinical dataset efficiently.
• Nonclinical Study Reports (Section 4.2): Section 4.2 contains full nonclinical study reports organized by discipline and study type. The nonclinical reports present detailed study designs, methodologies, results, and interpretations required for regulatory safety assessment. Within this section, pharmacology studies describe the mechanism of action and evaluate potential effects on major physiological systems. Pharmacokinetic studies present absorption, distribution, metabolism, and excretion (ADME) data that explain how the medicinal product behaves in biological systems and support exposure–response and dose selection decisions. Toxicology studies include single-dose and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and local tolerance evaluations that establish safety margins and identify potential risks associated with human exposure.

CTD Module 4 bridges the gap between quality development and clinical investigation. Module 4 evaluates the nonclinical pharmacology, pharmacokinetics, and toxicology of the medicinal product, forming the scientific basis for clinical development described in Module 5.

Regulatory authorities rely on CTD Module 4 to determine whether a medicinal product can be administered safely to humans and whether the proposed clinical development is adequately supported by nonclinical evidence. Incomplete or inconsistent nonclinical data can delay clinical authorization or trigger additional study requests. A well-structured Module 4 supports confident regulatory decision-making.

CTD Module 5: Clinical Study Reports (Efficacy)

CTD Module 5 is the clinical evidence component of the CTD and contains comprehensive reports from studies conducted in human subjects. CTD Module 5 provides the primary evidence supporting the medicinal product’s safety, efficacy, and overall clinical performance across all phases of development.

The sections included in CTD Module 5 are listed below.

• Table of Contents (Section 5.1): Section 5.1 provides a structured overview of all clinical documents included in Module 5. The table of contents allows regulators to navigate the clinical dataset efficiently and locate specific studies during review.
• Tabular Listing of Clinical Studies (Section 5.2): Section 5.2 presents a tabulated summary of all clinical studies conducted as part of the development program. The tabular listing of clinical studies helps regulators understand the scope, sequence, and purpose of the clinical investigations supporting the application.
• Clinical Study Reports (Section 5.3): Section 5.3 contains full clinical study reports organized by study type and development phase. Clinical study reports describe study design, conduct, analysis, and results for regulatory evaluation. Section 5.3 includes biopharmaceutic studies supporting formulation and dosage selection, pharmacokinetic and pharmacodynamic studies in humans defining exposure–response relationships, pivotal efficacy and safety trials demonstrating clinical benefit, and post-authorization studies, when applicable, supporting ongoing safety and effectiveness assessment.
• Literature References (Section 5.4): Section 5.4 includes relevant published literature used to support or contextualize the clinical development program.

CTD Module 5 represents the culmination of the CTD structure and demonstrates how the medicinal product performs in human populations under controlled clinical conditions.

Regulatory authorities rely on CTD Module 5 to determine whether the medicinal product is safe and effective for its intended use and whether the benefit–risk profile supports approval. Deficiencies in clinical data presentation, study documentation, or internal consistency can delay approval or lead to additional information requests. A complete and well-organized Module 5 supports efficient regulatory review and confident benefit–risk assessment.

What Are the ICH M4 Guidelines for Preparing the CTD?

The ICH M4 Guidelines define the internationally harmonized structure and content requirements for preparing the CTD used in medicinal product regulatory submissions. The ICH M4 guidelines ensure that quality, nonclinical, and clinical data are presented in a consistent format that can be efficiently reviewed by multiple regulatory authorities worldwide. The ICH M4 Guidelines establish how CTD information must be organized, summarized, and presented.

Below are listed the key areas addressed by the guidelines.

• CTD Organization and Structure: ICH M4 defines the standardized layout of CTD Modules 2 through 5, ensuring consistent document placement and a logical flow of information for regulatory review.
• Scientific Content Requirements: Under ICH M4, the guidance specifies the type and level of detail required for quality, nonclinical, and clinical data to meet regulatory expectations.
• Summary and Overview Standards: The ICH M4 framework outlines the requirements for preparing expert summaries and overviews to accurately interpret detailed data and support scientific assessments.
• Referencing and Cross-Linking Principles: According to ICH M4, summaries should reference underlying reports to maintain traceability across CTD modules.
• Cross-Regional Consistency: ICH M4 ensures that CTDs prepared in accordance with this guideline are acceptable to multiple regulatory authorities with minimal regional adaptation.

The ICH M4 Guidelines support regulatory harmonization by aligning the presentation of scientific data across regions. A CTD prepared according to ICH M4 can be reviewed by different authorities without restructuring, reducing duplication of work, shortening review timelines, and improving consistency in regulatory decision-making.

The ICH M4 framework is supported by several sub-guidelines that define requirements for specific CTD components, as outlined below.

• ICH M4 – Organization: The ICH M4 defines the overall CTD structure, including module arrangement, information flow, and separation of regional administrative content from harmonized scientific data.
• ICH M4Q – Quality: The ICH M4Q specifies the structure and content requirements for CTD Module 3, describing how CMC information for drug substances and drug products must be presented to demonstrate consistent product quality.
• ICH M4S – Nonclinical Safety: The ICH M4S defines how nonclinical pharmacology, pharmacokinetic, and toxicology data are organized within CTD Module 4, ensuring clear and comparable presentation of laboratory and animal study reports.
• ICH M4E – Clinical Efficacy: The ICH M4E establishes the structure and content requirements for CTD Module 5, governing the presentation of clinical study reports, efficacy data, safety outcomes, and statistical analyses supporting the benefit–risk evaluation.

M4: Organization

ICH M4: Organization defines the standardized structure and ordering of the CTD, ensuring a consistent and predictable dossier layout. The guideline specifies how CTD modules are arranged, how information flows across the submission, and how regional administrative content is separated from harmonized scientific data to support efficient regulatory review.

The purpose of ICH M4: Organization is to enable consistent regulatory assessment by providing a uniform framework that reviewers can navigate without needing to adapt to different dossier structures. A standardized layout enhances comparability between submissions, facilitates lifecycle management, and ensures consistent document placement across initial and follow-on applications.

ICH M4: Organization establishes the high-level CTD module structure, as outlined below.

• Module 1 – Regional Administrative Information: Module 1 contains country- or region-specific administrative, legal, and labeling documentation required by local authorities.
• Module 2 – CTD Summaries and Overviews: Module 2 provides integrated summaries and expert interpretations of the quality, nonclinical, and clinical data contained in Modules 3–5.
• Module 3 – Quality: Module 3 presents CMC information that demonstrates product quality, manufacturing control, and consistency.
• Module 4 – Nonclinical Study Reports: Module 4 contains nonclinical pharmacology, pharmacokinetics, and toxicology study reports supporting safety evaluation.
• Module 5 – Clinical Study Reports: Module 5 includes clinical study reports and supporting evidence used to evaluate safety, efficacy, and benefit–risk profile in humans.

Regulatory alignment across regions is supported through broad acceptance of the CTD structure by authorities such as the EMA and FDA, as well as other ICH and non-ICH regulatory agencies worldwide. Consistent module organization allows reuse of core scientific content across regions, reducing duplication and minimizing rework.

Predictable document placement improves the reviewer’s usability and dossier consistency. Regulators can locate evidence quickly, review timelines are shortened, and clarification requests are reduced, while applicants benefit from harmonized submissions and simpler dossier maintenance.

ICH M4: Organization governs dossier structure rather than scientific content by defining where administrative and technical documents belong within the CTD. Effective implementation of ICH M4: Organization depends on disciplined structure control, consistent naming, clear cross-referencing between summaries and detailed modules, and early planning to avoid late-stage restructuring.

M4Q: Quality

ICH M4Q establishes how quality-related information is presented within CTD Module 3, providing a harmonized framework for documenting chemistry, manufacturing, and controls (CMC). The guideline defines the structure and content of Module 3 (Quality) and Module 2.3 (Quality Overall Summary), ensuring regulators can review drug substance and drug product information in a clear, logical, and comparable manner.

ICH M4Q enables regulators to assess manufacturing consistency, control strategies, and product stability through a standardized and repeatable review approach. A consistent quality dossier structure improves transparency, supports cross-submission comparability, and facilitates lifecycle updates without reworking the core content.

ICH M4Q applies to the main quality sections of CTD Module 3, which include the following elements.

• 3.2.S – Drug Substance: The drug substance part of ICH M4Q documents the active pharmaceutical ingredient, covering manufacturing processes, characterization, material controls, specifications, analytical methods, reference standards, container closure systems, and stability data.
• 3.2.P – Drug Product: The drug product part of ICH M4Q describes the finished medicinal product, including formulation development, manufacturing operations, in-process controls, excipient control, specifications, analytical validation, container closure systems, and stability studies.
• 3.2.A – Appendices: The appendices section under ICH M4Q provides supporting quality information such as facility details, equipment descriptions, adventitious agent safety assessments, and novel excipient data when relevant.
• 3.2.R – Regional Information: The regional information section within ICH M4Q captures additional quality requirements imposed by specific authorities, supplementing the harmonized content without altering the overall Module 3 structure.

CMC review in both the EU and U.S., among other regulatory authorities, follows comparable principles, including expectations for controlled manufacturing, validated analytical methods, defined specifications, and scientifically justified shelf life. A standardized Module 3 layout allows reviewers to evaluate the same quality elements in predictable locations.

Consistent application of ICH M4Q reduces fragmented presentation of CMC evidence and supports global reuse of Module 3 content. Clear organization improves reviewer efficiency by making critical quality information easier to locate and assess.

Documentation under ICH M4Q includes manufacturing descriptions, process summaries, specifications, analytical procedures, validation reports, stability protocols and results, container closure information, and defined control strategies for critical quality attributes.

Strong ICH M4Q submissions result from close coordination between quality development, manufacturing, and regulatory teams. Aligning control strategies with specifications, ensuring stability conclusions reflect underlying data, and maintaining rigorous document control help preserve data integrity and reduce review questions.

M4S: Safety

ICH M4S establishes how nonclinical safety data are structured within the CTD, creating a harmonized framework for presenting pharmacology, pharmacokinetics, and toxicology evidence. The guideline defines the structure and content of Module 4 (Nonclinical Study Reports) as well as Module 2 Sections 2.4 (Nonclinical Overview) and 2.6 (Nonclinical Summaries), ensuring nonclinical findings are organized in a clear and consistent manner that supports reliable safety assessment.

ICH M4S enables regulators to evaluate nonclinical safety profiles using a predictable review approach by standardizing report categories and document placement. This structure supports the interpretation of biological risk before first-in-human exposure and alongside clinical development.

ICH M4S applies to the core nonclinical components of CTD Module 4, including the following areas.

• 4.2.1 – Pharmacology Reports: The pharmacology reports section under ICH M4S covers primary and secondary pharmacodynamics and safety pharmacology studies that describe the mechanism of action and potential physiological effects.
• 4.2.2 – Pharmacokinetic Reports: The pharmacokinetic reports section within ICH M4S includes absorption, distribution, metabolism, and excretion (ADME) studies that characterize systemic exposure and disposition.
• 4.2.3 – Toxicology Reports: The toxicology reports section, as defined by ICH M4S, contains single-dose and repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive toxicity, and local tolerance studies used to define safety margins.

Nonclinical evidence plays a critical role in dose selection, first-in-human trial decisions, and safety margin evaluation during regulatory review across multiple regions, including the EU and US. A harmonized Module 4 layout allows comparable study types to be reviewed in consistent locations across regions.

Clear organization under ICH M4S prevents fragmented presentation of safety data and inconsistent report placement. Structured Module 4 content supports reuse of nonclinical studies while enabling reviewers to rapidly identify key toxicology and safety pharmacology outcomes.

Materials prepared under ICH M4S typically include complete nonclinical study reports, protocols, methodologies, results, and supporting analyses, with clear links to nonclinical summaries in Module 2. Effective preparation depends on maintaining traceability, presenting study relevance clearly, and using consistent terminology across nonclinical and clinical risk discussions.

M4E: Efficacy

ICH M4E defines how clinical evidence is structured and presented within CTD Module 5 to support a clear and consistent evaluation of efficacy and safety in human subjects. The guideline defines the structure and content of Module 5 (Clinical Study Reports) as well as Module 2 Sections 2.5 (Clinical Overview) and 2.7 (Clinical Summary) to support a clear and consistent evaluation of efficacy and safety in human subjects.

Standardized organization under ICH M4E allows regulators to evaluate clinical development programs systematically, including study design, patient populations, endpoints, and outcomes. A predictable Module 5 structure enables efficient navigation from high-level clinical summaries to detailed study reports.

ICH M4E applies to the core clinical components of CTD Module 5, which include the following sections.

• 5.1 – Table of Contents: The table of contents section provides structured navigation across all clinical documents included in the module.
• 5.2 – Tabular Listing of Clinical Studies: The tabular listing section within ICH M4E presents an overview of all clinical studies conducted, outlining the scope, sequence, and purpose of the clinical program.
• 5.3 – Clinical Study Reports: The clinical study reports section, as defined by ICH M4E, contains full reports organized by study type, including biopharmaceutical studies, clinical pharmacology studies, and pivotal safety and efficacy trials.
• 5.4 – Literature References: The literature references section under ICH M4E includes published literature used to support, contextualize, or supplement the clinical data package.

Regulatory authorities across ICH regions, including the EU and the U.S., rely on structured clinical evidence to evaluate intended use, dosing rationale, safety profile, and therapeutic benefit. A harmonized Module 5 layout allows reviewers from different regulatory authorities, including the EMA and FDA, to locate critical study evidence and integrated clinical narratives in consistent locations, supporting efficient and comparable assessment across regions.

ICH M4E addresses common clinical dossier challenges by preventing fragmented presentation of clinical evidence and inconsistent study placement. Standardized report organization supports global reuse of clinical data while improving reviewer usability by enabling clear traceability from Module 2 clinical summaries to detailed reports in Module 5.

Typical documentation under ICH M4E includes complete clinical study reports, protocols, statistical analysis plans, efficacy and safety results, clinical pharmacology documentation, bioavailability or bioequivalence studies, and relevant supporting literature. Effective preparation relies on alignment between summaries and reports, consistent endpoint terminology, clear study naming conventions, and a clinical dataset that supports the proposed indication and labeling.

How Is the CTD Maintained Throughout a Medicinal Product’s Lifecycle?

The CTD is maintained throughout the medicinal product lifecycle by updating its content at key stages as new quality, nonclinical, and clinical information becomes available, such as during clinical trial progression, manufacturing process changes, post-approval variations, and safety updates.

The most common stages that require CTD updates are listed below.

• Development Stage: The development stage captures early nonclinical and clinical findings as the product progresses through Phase I, Phase II, and Phase III studies. CTD content expands as study results, protocols, and summaries are generated.
• Registration Stage: The registration stage consolidates final quality, safety, and efficacy data required to support a marketing authorization application. At this stage, the CTD represents a complete dossier for initial regulatory review.
• Post-Approval Stage: The post-approval stage incorporates new information generated after authorization, including manufacturing changes, updated stability data, and additional clinical results.
• Pharmacovigilance and Risk Management Stage: The pharmacovigilance and risk management stage integrates new safety signals, emerging risks, and periodic safety update data into labeling, clinical summaries, and benefit–risk evaluations.
• Lifecycle Optimization Stage: Lifecycle optimization introduces new formulations, strengths, dosage forms, manufacturing sites, or indications. Each change requires integration of new data into the relevant CTD modules.
• Technology Transfer Stage: The technology transfer stage outlines the transfer of manufacturing processes to new sites or partners, along with validation data and site information.
• Manufacturing Site Closure or Supply Chain Changes Stage: Manufacturing site closure or supply chain changes result in updates to compliance and validation documentation.
• Scale-Up and Commercial Manufacturing Stage: The scale-up and commercial manufacturing stage addresses process refinements, batch-size adjustments, and updated control strategies to maintain accurate quality documentation.
• Label Expansion or Indication Expansion Stage: Label or indication expansion stage records newly approved indications, populations, or dosing regimens and updates the related clinical summaries and labeling.
• Sunset / Withdrawal Stage: Sunset or withdrawal stage captures administrative updates related to discontinuation, withdrawal, or restricted distribution of the product.

CTD updates are driven by regulatory activities such as manufacturing variations, labeling changes, safety submissions, supplements, renewals, and annual reports. Each activity results in additions or revisions to the affected CTD modules to preserve dossier accuracy and completeness.

The sequence for maintaining lifecycle documentation begins with internal assessment of the impact, preparation of updated scientific or administrative content, internal review and approval, and submission to the regulatory authority in the required eCTD format. This process keeps the CTD aligned with the product’s approved and operational status.

Marketing Authorization Holders (MAHs) are responsible for maintaining the CTD throughout the product lifecycle. MAHs review new data, assess regulatory impact, update relevant CTD modules, and meet submission timelines. MAH’s responsibility includes maintaining accurate records and responding to regulatory authority requests during ongoing oversight.

CTD lifecycle management is supported by digital systems and structured processes. eCTD platforms enable electronic submissions and lifecycle tracking. Version control and change management systems ensure document accuracy and traceability. Regulatory intelligence and tracking tools monitor evolving regional requirements. Together, these tools help MAHs maintain a current, compliant, and inspection-ready CTD.

What Are the Most Common Challenges in the Preparation and Maintenance of CTD?

The most common challenges in the preparation and maintenance of the CTD are outlined below.

• Data Fragmentation Across Teams: CTD content is generated by multiple functions, including quality, clinical, regulatory, and manufacturing teams. When information is stored across disconnected systems, preparation becomes slower and more error-prone. Centralized document repositories and standardized templates help align content and reduce rework.
• Inconsistent Document Formats and Versions: Contributions from different authors can result in inconsistent formatting, naming conventions, and document versions. Format and version inconsistencies increase the risk of errors and regulatory queries. Controlled templates, version control, and structured authoring tools improve consistency and traceability.
• Frequent Regulatory Changes: Regulatory requirements for CTD content evolve over time and differ between regions. Changes to guidelines can affect both structure and scientific expectations. Ongoing regulatory intelligence monitoring and regular guideline reviews help teams maintain compliance.
• Complexity of Quality and Manufacturing Data: Module 3 contains highly detailed and technical CMC information. Errors or omissions in CMC documentation can delay approvals or trigger extensive follow-up questions. Clear internal workflows and early coordination between quality and regulatory teams support accurate documentation.
• Managing Safety Updates and New Clinical Data: New safety signals, updated risk profiles, and additional clinical results require timely updates to Modules 2 and 5. Delayed integration of new data can compromise lifecycle submissions. Strong cross-functional communication ensures updates are captured consistently.
• Maintaining a Current CTD Throughout the Lifecycle: Manufacturing changes, site transfers, process improvements, and labeling updates require frequent CTD revisions. Without defined maintenance processes, outdated information can accumulate. Formal change-control procedures help keep the dossier current.
• Coordinating Authors and Subject Matter Experts: CTD preparation involves multiple contributors with different timelines and responsibilities. Poor coordination can lead to gaps or delays. Clear role definitions, structured review cycles, and documented workflows improve efficiency.
• Managing Regional Requirements: Region-specific administrative and labeling requirements can result in duplicate work if not managed carefully. Familiarity with regional guidelines and reuse strategies reduces unnecessary revisions.
• Ensuring Submission-Ready Formatting for eCTD: CTD content must comply with eCTD technical specifications, including XML backbone structure, hyperlinks, and document granularity. Formatting errors can cause validation failures. Dedicated eCTD publishing and validation tools help prevent submission issues.

Effective tools support teams in mitigating these challenges. eCTD publishing platforms streamline electronic submissions and lifecycle tracking. Regulatory intelligence systems support alignment with evolving requirements. QMS software strengthens document control, version management, change management, and audit readiness, ensuring teams work with accurate, approved CTD content throughout the product lifecycle.

How Does Modern QMS Software Streamline CTD Preparation and Maintenance for Pharma Companies?

A modern QMS software streamlines CTD preparation and maintenance by centralizing documentation, controlling changes, and ensuring regulatory compliance across the entire product lifecycle. QMS software helps reduce errors, shortens timelines, and improves dossier consistency by replacing manual, fragmented processes with structured digital workflows.

The core QMS functions that directly support CTD activities are listed below.

• Document Control: Document control governs the creation, review, approval, versioning, and archival of CTD-related documents. Controlled access, version history, and approval status ensure that CTD modules always reference current and approved information.
• Change Management: Change management captures manufacturing changes, process updates, and labeling revisions that require CTD updates. Approved changes are linked to impacted CTD sections, ensuring that regulatory dossiers remain aligned with the product’s current state.
• Training Management: Training management confirms that personnel involved in CTD activities are qualified and trained on current procedures, templates, and regulatory expectations. Proper training reduces documentation errors and supports consistent, high-quality submissions.
• Deviation and CAPA Management: Deviation and Corrective and Preventive Action (CAPA) processes capture quality issues that may affect CTD content. Root-cause analysis and documented corrective actions support accurate updates to quality and regulatory documentation when required.
• Audit Management: Audit management supports internal and external audits related to CTD readiness. Audit outcomes identify documentation gaps, compliance risks, and areas that require corrective updates within CTD modules.

Modern QMS software solution reduces manual effort and errors in CTD compilation through automation and standardization. Standardized templates align documents with CTD structure requirements. Automated workflows route documents for review and approval without manual follow-up. Audit trails record every change, approval, and revision, strengthening traceability and reducing rework.

Ongoing CTD lifecycle updates are supported through integrated version control, impact assessment workflows, and change-linking across quality processes. When a process, specification, or safety requirement changes, the QMS highlights affected documents and ensures coordinated updates across CTD modules.

Pharmaceutical companies using QMS software for CTD management achieve measurable efficiencies, including fewer documentation errors, faster lifecycle updates, reduced duplicate work, and shorter submission preparation timelines. Centralized systems lower the risk of deviations caused by outdated information and improve consistency across global submissions.

QMS software for pharmaceutical companies, such as SimplerQMS, supports CTD preparation and maintenance by providing validated document control, structured change management, training oversight, and quality event tracking within a single platform. SimplerQMS helps pharmaceutical companies maintain accurate, inspection-ready CTD documentation while reducing administrative effort and supporting regulatory compliance throughout the product lifecycle.